Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-016220

Corvus Pharmaceuticals, Inc. · CRVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Richard A Miller M.D.
Officer — President and CEO · Director
Period of report
Jun 9, 2017
Accepted (ET)
Jun 13, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF1,F2Jun 9, 2017P5,000$9.95A982,293IBy Trust
Common Stock, $0.0001 par valueF1,F2Jun 9, 2017P3,784$9.89A986,077IBy Trust
Common Stock, $0.0001 par valueF3,F1,F2Jun 12, 2017P11,216$9.8239A997,293IBy Trust
Common Stock, $0.0001 par valueF1,F2Jun 13, 2017P2,500$9.75A999,793IBy Trust
Common Stock, $0.0001 par valueF1,F2Jun 13, 2017P2,500$10.14A1,002,293IBy Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses